Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05995405 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
A Phase 3 study of Aneurysmal Subarachnoid Hemorrhage (aSAH), sponsored by Grace Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05995405 is a Phase 3 study of Aneurysmal Subarachnoid Hemorrhage (aSAH) that is active but no longer recruiting, run by Grace Therapeutics. The registered enrollment target is 100 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05995405, a Phase 3 study of Aneurysmal Subarachnoid Hemorrhage (aSAH), is active but no longer recruiting, sponsored by Grace Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
Conditions Studied
Interventions
- DRUG GTX-104
- DRUG Nimotop 30 MG Oral Capsule
Study Locations (20)
Ohio
- University of Cincinnati Medical Center - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
North Carolina
- University of North Carolina - Chapel Hill
- Duke University - Durham
Tennessee
- Methodist University Hospital - Memphis
- Vanderbilt University Medical Center - Nashville
Alabama
- The University of Alabama at Birmingham - Birmingham
Arizona
- Brain and Spine Neurological Institute - Phoenix
California
- Community Regional Medical Center - Fresno
Florida
- Mayo Clinic Florida - Jacksonville
Georgia
- Emory University School of Medicine Emergency Neurosciences - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2024-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05995405
The ClinicalTrials.gov registry entry for NCT05995405 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grace Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aneurysmal Subarachnoid Hemorrhage (aSAH) appearing as the primary indexed condition, and to 2 interventions - of which GTX-104 is the first listed.
NCT05995405 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Ohio, North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05995405 about?
NCT05995405 is a clinical study titled "Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH". The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
What is the current status of trial NCT05995405?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2023-10-20. Estimated completion is 2024-12.
What conditions does trial NCT05995405 study?
This clinical trial studies the following conditions: Aneurysmal Subarachnoid Hemorrhage (aSAH).
What interventions are being tested in trial NCT05995405?
The interventions under investigation include: GTX-104 (DRUG), Nimotop 30 MG Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT05995405?
This trial is sponsored by Grace Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05995405 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aneurysmal Subarachnoid Hemorrhage (aSAH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.